Algorhythm Holdings Announces Changes to Board of Directors
September 10, 2024 07:00 ET
|
Algorhythm Holdings, Inc.
Executive Chairman and Two Other Directors Voluntarily Resign Fort Lauderdale, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME) – an AI...
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
September 10, 2024 07:00 ET
|
Mural Oncology, Inc.
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the...
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
September 10, 2024 07:00 ET
|
TFF Pharmaceuticals, Inc.
TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to assess additional influenza strains FORT...
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
September 10, 2024 06:57 ET
|
Aclarion, Inc.
Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial...
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
September 10, 2024 06:35 ET
|
Silo Pharma, Inc.
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ...
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
September 10, 2024 06:30 ET
|
Roivant Sciences
Mosliciguat is a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability...
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
September 10, 2024 06:30 ET
|
Roivant Sciences
Mosliciguat, a potential first-in-class and best-in-category inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, is being developed for...
Affimed to Present at the Cantor Global Healthcare Conference 2024
September 10, 2024 06:30 ET
|
Affimed N.V.
MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
XCHG Limited Announces Pricing of Initial Public Offering
September 10, 2024 06:00 ET
|
XCHG LIMITED
HAMBURG, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- XCHG Limited (“XCharge” or the “Company”) (NASDAQ: XCH), a global leader in integrated EV charging solutions, today announced the pricing of its...
Inception Growth Acquisition Limited Announces Additional Contribution to Trust Account to Extend Business Combination Period
September 10, 2024 06:00 ET
|
Inception Growth Acquisition Limited
New York, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Inception Growth Acquisition Limited (NASDAQ: IGTA, the “Company”), a publicly traded special purpose acquisition company, announced today that on...